Bernfort Lars
Center for Medical Technology Assessment, Linkoping University, Linkoping, Sweden.
Health Care Anal. 2003 Dec;11(4):301-8. doi: 10.1023/B:HCAN.0000010059.61453.8e.
Inclusion or not of a treatment strategy in the publicly financed health care is really a matter of prioritisation. In Sweden priority setting decisions are governed by law in which it is stated that decisions should be guided by firstly the principle of need and secondly the principle of cost-effectiveness.
The purpose of the paper is to discuss and illustrate the roles of need and cost-effectiveness in decisions on inclusion or not of treatment strategies in the publicly financed health care.
The theoretical backgrounds of need and cost-effectiveness are discussed in short, both with respect to their meaning and to their potential roles in decisions on priority setting. Four treatment strategies, Viagra, Rivastigmine, statins, and lung transplants, are analysed with respect to whether either cost-effectiveness or need, or both, seem to have played a role in the decisions of inclusion or not in the basic health care package.
Both need and cost-effectiveness are important and should be important aspects when making decisions on priority setting. From the examples of the four treatment strategies it seems that decisions are almost exclusively made with reference to the principle of need.
The most evident conclusion to be drawn from this study is that decisions on priority setting are almost solely based on the principle of need. This implies that the principle of cost-effectiveness is given very little space, which is a problem as this means an obvious risk of inefficient resource use.
公共资助的医疗保健中是否纳入某种治疗策略实际上是一个优先排序的问题。在瑞典,优先排序决策受法律管辖,法律规定决策应首先遵循需求原则,其次遵循成本效益原则。
本文旨在讨论并说明需求和成本效益在公共资助医疗保健中治疗策略纳入与否的决策中的作用。
简要讨论了需求和成本效益的理论背景,包括它们的含义以及在优先排序决策中的潜在作用。分析了四种治疗策略,即伟哥、卡巴拉汀、他汀类药物和肺移植,探讨成本效益或需求,或两者是否在基本医疗保健套餐纳入与否的决策中发挥了作用。
需求和成本效益都很重要,且在做出优先排序决策时应是重要方面。从这四种治疗策略的例子来看,决策似乎几乎完全参照需求原则。
从本研究中得出的最明显结论是,优先排序决策几乎完全基于需求原则。这意味着成本效益原则的空间很小,这是一个问题,因为这意味着资源使用效率低下的明显风险。